Europe · Markets & Finance · Proactive Investors

Lilly's triple GLP-1 combination raises the stakes for Novo Nordisk

Published by Proactive Investors · United Kingdom 11 h ago

Eli Lilly's experimental obesity drug combination has delivered weight loss of up to 23.3% in a mid-stage trial, adding to pressure on rival Novo Nordisk, according to Citi. The…

Read the full article on Proactive Investors Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.proactiveinvestors.co.uk)

Also worth reading

City A.M.

Chef’s Table: Victor Garvey interviews top Japanese actress Yoh Yoshida

This is Money

Manchester City should face criminal probe over estimated £12m in unpaid tax, experts claim

Financial Times

Lilly's triple GLP-1 combination raises the stakes for Novo Nordisk

Share

Also worth reading

Chef’s Table: Victor Garvey interviews top Japanese actress Yoh Yoshida

Manchester City should face criminal probe over estimated £12m in unpaid tax, experts claim

International Criminal Court cuts ties with Axa over US sanctions

Gold struggles as elevated US Treasury yields outweigh dovish Fed repricing

Bonds fend off bears; Micron results boost tech stocks

Romania's political stalemate intensifies rating pressure before S&P review